Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

Journavx: A Promising Opioid Alternative, but Not a Silver Bullet

by January 31, 2025
January 31, 2025
Journavx: A Promising Opioid Alternative, but Not a Silver Bullet

Jeffrey A. Singer

On January 30, the Food and Drug Administration announced it approved the first of a new class of pain reliever drugs as an alternative to opioids. Journavx (generic name suzetrigine) was found to work as well as hydrocodone (Vicodin, Norco) to treat moderate to severe postoperative pain in two Phase 3 clinical trials, one with patients who underwent bunionectomy surgery and another on patients who underwent abdominoplasty. 

The drug is unique in that, unlike opioids, which directly target the brain to dull the perception of pain, or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen, which reduce inflammation and pain at the injury site, suzetrigine blocks the nerves that transmit pain signals to the brain.

The Phase 1 trials of suzetrigine took place in 2021. The entire approval process took only about four years, which is not typical for the FDA. The process usually takes about 10–15 years, and the Phase 1–3 clinical trials process generally takes around 6–7 years, followed by 10 months for standard FDA review (6 months for accelerated review). According to a report from the trade association BIO, 90 percent of drugs don’t make it through the Phase 1 approval process. A 2024 study published in the Journal of the American Medical Association estimated the mean cost of bringing a drug to market from 2000 to 2018 to be “$879.3 million when both drug development failure and capital costs were included.”

The FDA accelerated suzetrigine’s approval through its Overdose Prevention Framework, streamlining the clinical trial and approval process for opioid substitutes and harm-reduction products such as overdose antidotes. This demonstrates that the FDA can dramatically reduce the regulatory burden on new drug development when it deems a problem urgent. However, the FDA—not the patients suffering from specific conditions—decides what qualifies as urgent.

The FDA created the accelerated framework based on the debunked narrative that the overdose crisis was caused by doctors hooking their patients on opioids. As I have written, the overdose crisis resulted from a growing population of nonmedical drug users accessing drugs in the increasingly dangerous black market caused by drug prohibition. Substance Abuse and Mental Health Services Administration (SAMHSA) surveys begun in 2002 consistently show the addiction rate to prescription pain pills has never exceeded 0.8 percent of adults over age 18 (see attached graph). 

As early as 2017, I pointed out that overdose rates began to climb as doctors started cutting back on opioid prescribing, which reduced nonmedical users’ access to diverted pain pills and drove them to more dangerous heroin and, now, fentanyl.

Nevertheless, Journavx appears to be a real breakthrough drug, opening the door for a new class of pain relievers for patients to access. This is good news.

A caveat: Pain is subjective, and analgesics affect individuals differently. The clinical trials found it roughly equivalent to a standard dose of hydrocodone. Hydrocodone is not as potent as oxycodone and doesn’t work for everyone, though it works for many people.

Clinicians must still be ready to prescribe oxycodone or something even more potent if this new drug fails to provide the relief patients require. I worry that many doctors might resort to prescribing this drug exclusively and abandon opioid alternatives altogether due to fear of disciplinary action from cops practicing medicine.

0
FacebookTwitterGoogle +Pinterest
previous post
Abramovich faces fresh calls for HMRC probe over potential £1bn tax bill
next post
Should the US Respond to “Unfair” Trade Practices?

You may also like

Milei’s Key Pending Task: Ending Argentina’s Currency Controls...

January 10, 2025

Punishing Drug Use: The Failure of Coercive Policies...

April 7, 2025

SCOTUS Sidesteps Section 230

May 19, 2023

Decentralized Networks and Separated Powers: An Historic Moment...

May 23, 2024

Friday Feature: Masterpiece Academy

June 28, 2024

The Wrong Door: Federal Agents Raid the Wrong...

March 21, 2025

Why So Much Public Land?

February 20, 2025

FISA Reform: Dueling Proposals,Ticking Clock

December 5, 2023

Latest Attempt to Restore Financial Privacy: the Saving...

September 25, 2024

The Republican Study Committee Budget on the Key...

June 16, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • MP launches bill to make polluters pay for climate damage and resilience

      May 15, 2025
    • HMRC issues first individual tax avoidance Stop Notices to former solicitor Paul Baxendale-Walker

      May 15, 2025
    • UK economy posts strongest growth in a year, driven by exports and business investment

      May 15, 2025
    • EIS investments fall sharply despite tax breaks, raising concerns over regional imbalance and complexity

      May 15, 2025
    • University of Hull launches Railwhere to drive innovation in rail freight efficiency

      May 15, 2025
    • Bank of London under investigation by PRA amid financial uncertainty and governance overhaul

      May 15, 2025

    Categories

    • Business (7,966)
    • Investing (1,959)
    • Politics (15,225)
    • Stocks (3,084)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved